Chimeric Adenoviral (Ad5.F35) and Listeria Vector Prime-Boost Immunization Is Safe and Effective for Cancer Immunotherapy

Researchers examined a prime-boost strategy using a chimeric adenoviral vector that resisted pre-existing immunity followed by recombinant Listeria monocytogenes to amplify immunity to the gastrointestinal cancer antigen GUCY2C.